David Scadden is Director of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 15,483 shares of AGIO, which is worth approximately $734,358. The most recent transaction as insider was on Jun 13, 2024, when has been sold 3,388 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.5K
28.01% 3M change
28.01% 12M change
Total Value Held $734,358

David Scadden Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 13 2024
BUY
Exercise of conversion of derivative security
-
3,388 Added 17.95%
15,483 Common Stock
Jun 21 2023
BUY
Exercise of conversion of derivative security
-
4,975 Added 29.14%
12,095 Common Stock
May 20 2022
BUY
Exercise of conversion of derivative security
-
1,585 Added 18.21%
7,120 Common Stock
May 28 2021
BUY
Exercise of conversion of derivative security
-
1,686 Added 23.35%
5,535 Common Stock

Also insider at

MGTA
Magenta Therapeutics, Inc. Healthcare
EDIT
Editas Medicine, Inc. Healthcare
SESN
Sesen Bio, Inc. Healthcare
DS

David Scadden

Director
Cambridge, MA

Track Institutional and Insider Activities on AGIO

Follow AGIOS PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AGIO shares.

Notify only if

Insider Trading

Get notified when an Agios Pharmaceuticals, Inc. insider buys or sells AGIO shares.

Notify only if

News

Receive news related to AGIOS PHARMACEUTICALS, INC.

Track Activities on AGIO